Chronic hepatitis C - direct-acting antiviral (DAA) therapy
Chronic HCV, DAA, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, pangenotypic, SVR · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic HCV (HCV RNA positive) is curable with 8-12 weeks of oral pangenotypic DAAs achieving sustained virological response (SVR, cure) in >95%. Treatment is recommended for ALL infected patients. Simplified genotype-free regimens apply to treatment-naive adults without cirrhosis or with compensated cirrhosis. Cure reduces progression, HCC risk and transmission.
Red flags
- Decompensated cirrhosis (ascites, encephalopathy, variceal bleed) - changes regimen, specialist-led
- HBV coinfection - reactivation during/after DAA (monitor ALT/HBV DNA)
- Amiodarone + sofosbuvir - symptomatic bradycardia
- Signs of hepatocellular carcinoma
- Significant drug-drug interactions (anticonvulsants, rifampicin reduce DAA levels)
Assessment
Differential diagnosis
- Other causes of raised ALT: MASLD, alcohol, HBV, autoimmune, haemochromatosis
- HCV/HIV or HCV/HBV coinfection
- Acute vs chronic HCV
- Decompensated cirrhosis (changes regimen - no protease inhibitor)
Investigations
- HCV antibody then confirmatory HCV RNA (viraemia); HCV genotype not needed for pangenotypic simplified therapy
- Assess cirrhosis: FibroScan / FIB-4 / APRI; examine for decompensation
- HBsAg, anti-HBc, HBV DNA (reactivation risk), HIV test, anti-HAV immunity
- FBC, LFTs, U&E/eGFR, INR; baseline before and after therapy for SVR
- Pregnancy test; full medication reconciliation for drug-drug interactions (statins, amiodarone, anticonvulsants, rifampicin, PPIs, ethinylestradiol)
- HCV RNA at 12 weeks after end of treatment to confirm SVR12 (cure)
Management
- Confirm viraemia (HCV RNA positive) and stage fibrosis (identify cirrhosis and whether compensated or decompensated)
- Screen for HBV coinfection - risk of HBV reactivation during DAA therapy (prophylaxis/monitoring if HBsAg+)
- Check comprehensive drug-drug interactions (use HEP drug interaction checker)
- Select pangenotypic regimen: glecaprevir/pibrentasvir 8 weeks (no cirrhosis or compensated cirrhosis) OR sofosbuvir/velpatasvir 12 weeks
- Decompensated (Child-Pugh B/C) cirrhosis: AVOID protease inhibitors (glecaprevir, voxilaprevir) - use sofosbuvir/velpatasvir +/- ribavirin, hepatology-led
- Treat; counsel on adherence, reinfection risk, and avoiding alcohol
- Confirm cure with HCV RNA (SVR12) 12 weeks after completion
- After cure: continue HCC surveillance if cirrhosis (cure does NOT remove HCC risk in established cirrhosis); manage reinfection risk
Drugs & doses
Glecaprevir/pibrentasvir 300 mg/120 mg (3 tablets) PO once daily WITH food for 8 weeks (treatment-naive, no or compensated cirrhosis); 12-16 weeks in some experienced patients [verify local]
Sofosbuvir/velpatasvir 400 mg/100 mg (1 tablet) PO once daily for 12 weeks (pangenotypic alternative; usable across fibrosis stages)
Decompensated cirrhosis: sofosbuvir/velpatasvir + weight-based ribavirin 12 weeks (specialist) - NO protease inhibitor
Prior DAA failure / salvage: sofosbuvir/velpatasvir/voxilaprevir 12 weeks (not in decompensated cirrhosis)
Avoid glecaprevir/pibrentasvir in Child-Pugh B/C cirrhosis (hepatotoxicity)
Manage interactions: avoid/limit PPIs with some regimens, adjust statins, avoid amiodarone with sofosbuvir (bradycardia), ethinylestradiol contraindicated with glecaprevir/pibrentasvir
HBV prophylaxis (entecavir/tenofovir) if HBsAg+ during DAA therapy [verify local]
Disposition
Outpatient specialist/community HCV service. Hepatology for cirrhosis (especially decompensated), prior treatment failure, or complex interactions. Admit only for decompensation or HCC.
Complications & pitfalls
- Cirrhosis, portal hypertension, decompensation
- Hepatocellular carcinoma (risk persists after cure if cirrhotic)
- HBV reactivation during therapy
- Extrahepatic: cryoglobulinaemic vasculitis, membranoproliferative GN, lymphoma, porphyria cutanea tarda
- Reinfection if ongoing exposure (not immunity-conferring)
Exam pearls
- AASLD-IDSA HCV guidance: treat ALL patients with chronic HCV (except very short life expectancy) - pangenotypic DAAs cure >95% in 8-12 weeks.
- Simplified genotype-FREE treatment applies to treatment-naive adults without cirrhosis or with compensated cirrhosis; genotype/RAS testing not required.
- NEVER use a protease inhibitor (glecaprevir, voxilaprevir) in DECOMPENSATED (Child-Pugh B/C) cirrhosis - use sofosbuvir/velpatasvir-based therapy.
- Always screen for HBV before DAAs - reactivation can be severe; monitor or give antiviral prophylaxis if HBsAg+.
- Cure (SVR12) does NOT stop HCC surveillance in patients who already have cirrhosis. Check drug interactions every time (statins, amiodarone, anticonvulsants, PPIs).
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.